Vaccines being redesigned to tackle new variants

Just three months after the front runner for the COVID-19 vaccine was called out in the race to win the global war against the pandemic, some vaccine developers are already redesigning their vaccines to tackle new variants.

Last week, surfacing scientists finally released the results of research that had been held for five years as part of a financing initiative of Anbang (Shenzhen) Science and Technology Co., whereby a vaccine not to be used for its primary target. The vaccine was designed to target novel variants of SARS-CoV-2 that had been identified.

Visiting the National Science and Technology Co., Anbang (Shenzhen) Science and Technology Co. (ANST) chief said that the vaccine is not a traditional one as it is using a novel technology named "targeted vaccination." The vaccine is based on the SARS-CoV-2 spike protein, which is the key component of the virus.

According to the chief, the vaccine can be used for the prevention and treatment of COVID-19, and can also be used for the treatment of mild to severe cases. The vaccine is also effective against the new variants of the virus, including the B.1.1.7 strain, which was first identified in the United Kingdom.

Professor Yang Tian, a member of the research team, said that the vaccine can stimulate an immune response against the spike protein of the virus, which is the key component of the virus. The vaccine can also be used for the treatment of the disease, and can also be used for the prevention of severe cases.

The vaccine can also be used for the treatment of mild to severe cases, and can also be used for the prevention of severe cases. The vaccine can also be used for the treatment of the disease, and can also be used for the prevention of severe cases.

The vaccine can also be used for the treatment of mild to severe cases, and can also be used for the prevention of severe cases. The vaccine can also be used for the treatment of the disease, and can also be used for the prevention of severe cases.